Brittany Lapin1, Julie Piorkowski2, Dennis Ownby3, Sally Freels2, Noel Chavez4, Eva Hernandez2, Cynthia Wagner-Cassanova2, Darlene Pelzel2, Carmen Vergara2, Victoria Persky2. 1. Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois. Electronic address: brittany.lapin@gmail.com. 2. Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois. 3. Section of Allergy and Immunology, Georgia Regents University, Augusta, Georgia. 4. Community Health Sciences Division, School of Public Health, University of Illinois at Chicago, Chicago, Illinois.
Abstract
BACKGROUND: Asthma prevalence has doubled in developed countries during the past 30 years. Pre- and perinatal events are essential in shaping the development of the immune system and systemic antibiotic use during this time could alter the maternal or placental microbiome, leading to an increase in the child's risk of developing asthma. OBJECTIVE: To determine whether prenatal antibiotic use is associated with asthma and wheezing in children at risk for asthma. METHODS: Using data from a randomized education intervention of families at risk for asthma from 1998 followed through 2009 in urban Chicago, asthma was defined as ever having a physician asthma diagnosis by year 3 and wheezing in the third year. Logistic regression models controlling for confounders investigated the effect of antibiotic use during pregnancy on these outcomes. RESULTS: After adjustment, prenatal antibiotic use was a risk factor for asthma (odds ratio 3.1, 95% confidence interval 1.4-6.8) but was only weakly associated with wheezing (odds ratio 1.8, 95% confidence interval 0.9-3.3). Analyses of the effects of timing of prenatal antibiotic use on asthma and wheezing showed the relation remained consistent for antibiotic use later in pregnancy, but the outcomes were not associated with antibiotic use in the first trimester. CONCLUSION: This study suggests prenatal antibiotic use might be associated with the development of asthma in children at risk for asthma. Although the relation with prenatal antibiotics does not hold for wheezing in this study, there might be a trend that could be delineated further within a larger cohort study.
BACKGROUND:Asthma prevalence has doubled in developed countries during the past 30 years. Pre- and perinatal events are essential in shaping the development of the immune system and systemic antibiotic use during this time could alter the maternal or placental microbiome, leading to an increase in the child's risk of developing asthma. OBJECTIVE: To determine whether prenatal antibiotic use is associated with asthma and wheezing in children at risk for asthma. METHODS: Using data from a randomized education intervention of families at risk for asthma from 1998 followed through 2009 in urban Chicago, asthma was defined as ever having a physician asthma diagnosis by year 3 and wheezing in the third year. Logistic regression models controlling for confounders investigated the effect of antibiotic use during pregnancy on these outcomes. RESULTS: After adjustment, prenatal antibiotic use was a risk factor for asthma (odds ratio 3.1, 95% confidence interval 1.4-6.8) but was only weakly associated with wheezing (odds ratio 1.8, 95% confidence interval 0.9-3.3). Analyses of the effects of timing of prenatal antibiotic use on asthma and wheezing showed the relation remained consistent for antibiotic use later in pregnancy, but the outcomes were not associated with antibiotic use in the first trimester. CONCLUSION: This study suggests prenatal antibiotic use might be associated with the development of asthma in children at risk for asthma. Although the relation with prenatal antibiotics does not hold for wheezing in this study, there might be a trend that could be delineated further within a larger cohort study.
Authors: Kjersti Aagaard; Jun Ma; Kathleen M Antony; Radhika Ganu; Joseph Petrosino; James Versalovic Journal: Sci Transl Med Date: 2014-05-21 Impact factor: 17.956
Authors: S Dom; J H J Droste; M A Sariachvili; M M Hagendorens; E Oostveen; C H Bridts; W J Stevens; M H Wieringa; J J Weyler Journal: Clin Exp Allergy Date: 2010-06-07 Impact factor: 5.018
Authors: N E Lange; J C Celedón; E Forno; N P Ly; A Onderdonk; L Bry; M L Delaney; A M DuBois; D R Gold; S T Weiss; A A Litonjua Journal: Clin Exp Allergy Date: 2012-06 Impact factor: 5.018
Authors: Esther Hafkamp-de Groen; Agnes M M Sonnenschein-van der Voort; Johan P Mackenbach; Liesbeth Duijts; Vincent W V Jaddoe; Henriëtte A Moll; Albert Hofman; Johan C de Jongste; Hein Raat Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: M O Coker; A G Hoen; E Dade; S Lundgren; Z Li; A D Wong; M S Zens; T J Palys; H G Morrison; M L Sogin; E R Baker; M R Karagas; J C Madan Journal: BJOG Date: 2019-06-05 Impact factor: 6.531
Authors: Christian Milani; Sabrina Duranti; Francesca Bottacini; Eoghan Casey; Francesca Turroni; Jennifer Mahony; Clara Belzer; Susana Delgado Palacio; Silvia Arboleya Montes; Leonardo Mancabelli; Gabriele Andrea Lugli; Juan Miguel Rodriguez; Lars Bode; Willem de Vos; Miguel Gueimonde; Abelardo Margolles; Douwe van Sinderen; Marco Ventura Journal: Microbiol Mol Biol Rev Date: 2017-11-08 Impact factor: 11.056
Authors: A Cait; M R Hughes; F Antignano; J Cait; P A Dimitriu; K R Maas; L A Reynolds; L Hacker; J Mohr; B B Finlay; C Zaph; K M McNagny; W W Mohn Journal: Mucosal Immunol Date: 2017-10-25 Impact factor: 7.313